Table 4.

Neonatal outcomes of study population

Characteristics	Intra-amniotic inflammation (−)/ MIAC (−) (Group 1, n=102)	P*	Adjusted P*,§	Intra-amniotic inflammation (+)/ MIAC (−) (Group 2, n=48)	P†	Intra-amniotic inflammation (+)/ MIAC (+) (Group 3; n=18)	P‡	Adjusted P‡,§
Neonatal death	5/102 (5%)	NS	NS	6/48 (13%)	NS	4/18 (22%)	NS	NS
Significant morbidity**,††	19/101 (19%)	.006	.012	21/42 (50%)	NS	8/15 (53%)	NS	NS
Respiratory distress syndrome	13/101 (13%)	NS	NS	5/42 (12%)	NS	3/15 (20%)	NS	NS
Bronchopulmonary dysplasia	10/97 (10%)	.002	.015	18/42 (43%)	NS	4/15 (27%)	NS	NS
Intraventricular hemorrhage	8/101 (8%)	NS	NS	2/42 (5%)	NS	4/15 (27%)	NS	NS
Necrotizing enterocolitis	3/101 (3%)	NS	NS	4/42 (10%)	NS	0/15	NS	NS
Proven early neonatal sepsis	1/101 (1%)	NS	NS	1/42 (2%)	NS	0/15	NS	NS
Neonatal death and/or any significant morbidity	21/102 (21%)	.002	.007	27/48 (56%)	NS	11/18 (61%)	.011	NS

Data presented as n/N (%).

MIAC, microbial invasion of amniotic cavity; NS, not significant.

^*Comparison between groups 1 and 2.

^†Comparison between groups 2 and 3.b

^‡Comparison between groups 1 and 3.

^§Adjusted for gestational age at amniocentesis and the cervical dilatation (generalized estimation equation models).

^**Defined as the presence of any of the following conditions: proven early neonatal sepsis, respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, and necrotizing enterocolitis.

^††Ten cases were excluded from the analysis because they died shortly after delivery as a result of extreme prematurity and thus could not be evaluated with respect to the presence or absence of neonatal morbidity.